CRVO

2.19 +0.01 (+0.46%)

CervoMed Inc. · NASDAQ

Performance

+5.64%

1W

-3.36%

1M

-84.93%

3M

-86.74%

6M

-7.91%

YTD

-76.06%

1Y

Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Technical Analysis of CRVO 2025-01-21

The stock's Moving Average Score of 16 indicates a strong bearish sentiment, while the Oscillators Score of 50 reflects a neutral stance. Overall, the combined Technical Score of 33 reinforces a bearish outlook, suggesting caution for potential investors.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of CRVO

Created with Highcharts 11.1.055005547470100
QualityGrowthMomentumValue4

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.